A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)

Exclusion Criteria

• •Participant has had chemotherapy, radiotherapy or biological therapy within the past 4 weeks.
• •Participant is currently receiving other anti-cancer therapy.
• •Participant is currently participating or has participated in a study with an investigation drug or device within the last 30 days.
• •Participant has a primary central nervous system tumor or active brain metastases.
• •Participant has a psychiatric disorder.
• •Participant uses illegal drugs.
• •Participant is pregnant or breastfeeding.
• •Participant is known to be human immunodeficiency virus (HIV) positive.
• •Participant has a known history of Hepatitis B or C.
• •Participant has newly diagnosed diabetes.
• •Participant has an active infection.
• •Participant is unable to swallow capsules.
• •Participant has received a blood transfusion with one week of study entry.
• •Participant has a history of cardiac problems including heart failure, myocardial infarction, unstable angina, congestive heart failure or cardiac arrhythmia.
• •Participant has a known sensitivity to the components of the study drug.
• •Participant has not adequately recovered from any prior surgical procedure.
• •Participant does not agree to refrain from use of herbal remedies and consumption of grapefruit juice for 2 weeks prior to and during the study.